Universiti Kuala Lumpur Royal College of Medicine Perak (UniKL RCMP) has taken a significant step toward enhancing Malaysia’s pharmacovigilance and surveillance ecosystem by hosting the Seminar & Workshop on Robust Pharmacovigilance and Surveillance in Malaysia from 6 to 8 October 2025.
Held at Royale Chulan Damansara Hotel, the three-day programme gathered 156 participants representing government agencies, academia, and the pharmaceutical and cosmetic industries.
Organised to strengthen national understanding and adoption of pharmacovigilance and post-market surveillance practices, the event aligned closely with Malaysia’s regulatory priorities.
It also served as a strategic platform for knowledge exchange between the National Pharmaceutical Regulatory Agency (NPRA), health practitioners, and industry leaders.
The seminar opened with remarks by UniKL President/Chief Executive Officer, YBhg. Prof. Ir. Dr. Azman Senin, followed by an officiating address from YBhg. Dr. Azuana Ramli, Deputy Director General of Health (Pharmaceutical Services), Ministry of Health Malaysia.
In his speech, YBhg. Prof. Ir. Dr. Azman underscored UniKL’s commitment to advancing healthcare education and regulatory competency through collaborative initiatives and lifelong learning.
YBhg. Dr Azuana, meanwhile, highlighted the need to strengthen pharmacovigilance systems and surveillance practices to safeguard patient safety and uphold the integrity of the national healthcare ecosystem.
Over the course of the programme, NPRA experts delivered comprehensive presentations on key topics, including Good Vigilance Practice (GVP) inspections, adverse reaction reporting, risk-based product quality monitoring, and post-market surveillance for cosmetics.
Industry insights were also shared by representatives from the Pharmaceutical Association of Malaysia (PhAMA) and the Malaysian Organisation of Pharmaceutical Industries (MOPI).
The seminar concluded with a call to strengthen collaboration between regulators, academia, and industry, an essential foundation for building a transparent, efficient, and patient-centred national pharmacovigilance system.
